Study of Ibrutinib in Relapsed and Refractory T-cell Lymphoma
Status:
Recruiting
Trial end date:
2022-12-01
Target enrollment:
Participant gender:
Summary
This is a Phase 1 clinical trial, a type of research study. The purpose of this phase 1
clinical trial is to find out whether a new study drug, ibrutinib, is safe in patients with
T-cell non-Hodgkin lymphoma that has either come back or not responded to treatment. In this
phase 1 study, different doses of ibrutinib (560 mg and 840 mg daily) will be tested to see
what effect the drug has on the patient and the disease.
Phase:
Phase 1
Details
Lead Sponsor:
Memorial Sloan Kettering Cancer Center
Collaborators:
Janssen Biotech, Inc. Ohio State University Pharmacyclics LLC.